INTRODUCTION
Phase III randomized clinical trials (RCTs) are considered to be the gold standard in assessing medical interventions. 1 The findings from RCTs enable clinicians to provide treatment recommendations, describe the risks and benefits of various treatments, and facilitate shared decision making. The CONSORT statement was developed by the International Committee of Medical Journal Editors to ensure clarity and transparency for the reporting of clinical trials. [2] [3] [4] As a result, the overall quality of RCT reporting has improved. 5 Subgroup analyses are important elements of clinical trial results reporting. Only average results are reported in RCTs, and trial participants are frequently recruited from a heterogeneous population. It could well be that treatment did not work or even had an adverse effect in a number of participating patients. The results of subgroup analyses can be important to identify the nonresponders, or the subset who can benefit most from the treatment. [6] [7] [8] [9] Therefore, treatment effects in subgroups may offer clinicians greater insight into treating individual patients, which is particularly appealing in the field of medical oncology because oncology drugs have lower therapeutic indices but higher toxicity compared with drugs in other therapeutic areas. 10, 11 However, subgroup analyses can also introduce analytic challenges and can lead to overstated and misleading results.
12 Thus, some treatments may be withheld for some patients who require them, and some other patients may be treated with drugs that are not needed. Prompted by such situations, the CONSORT statement, which provides guidance to authors regarding essential items that should be included in RCT reports, was updated in 2001 and 2010 to incorporate new elements. Several recommendations regarding the appropriate reporting of subgroup analyses have been generated in the CONSORT statement, with accompanying explanations and examples of appropriate reporting and analyses. 3, 4 The interpretation of subgroup analyses is potentially important for treatment decisions in medical oncology. Although subgroup analyses are commonly used and comprise an important part of oncologic RCTs publications, little attention has been given to their adequate reporting and interpretation. We describe the clarity and completeness of subgroup analyses in contemporary oncology publications of randomized phase III trials, and evaluate the authors' interpretations and justifications of the subgroup analyses results in the context of CONSORT recommendations.
METHODS

Trial Selection
We searched MEDLINE via PubMed (http://www.pubmed.gov) to identify all publications of phase III RCTs assessing systemic therapies for solid tumors published between January 1, 2011, and December 31, 2013. The search was performed in April 2014, using the following keywords: cancer and either controlled clinical trials or phase III trials. Publications were limited to trials exploring pharmacologic interventions in patients with solid tumors. Exclusion criteria included pediatric studies (Ͻ 18 years of age), observational studies, case reports, editorials, letters, meta analyses, publications using pooled data from two or more trials, phase I and II studies, studies exploring device or behavioral interventions, hematologic studies, and supportive care studies. In cases in which multiple publications were identified from the same trial, the initial publication was used for the analysis.
Data Extraction
The CONSORT statement (item 12b and 18) includes recommendations to improve the analysis and reporting of subgroup analyses in RCTs. 3, 4 This statement indicates that subgroup analyses should use prespecified subgroups and interaction tests, should be limited to a few important clinical questions, and should be completely reported (Table 1) .
Eligible publications were evaluated to determine whether any subgroup analyses were reported. For trials reporting subgroup analyses, information about subgroup analyses was extracted, which was considered essential to evaluate the appropriateness of the method and the validity of the results. We recorded where within the article the subgroup analyses were reported; that is, whether the results were presented only in the text versus also in tables or figures (either in the main body of text or in supplementary material), and whether treatment comparison information was presented for the different levels of a subgroup variable. We also attempted to determine the number of subgroup analyses that were performed and the number of subgroup analyses that were reported, the number of subgroup factors, the types of subgroup factors (whether they are clinical factors such as sex, tumor stage, or biomarkers such as estrogen expression), whether it was clear that each subgroup analysis was prespecified or post hoc, whether statistical methods (interaction tests, subgroup P values, and CI, or descriptive only) were used to assess heterogeneity of treatment effects, and whether subgroup difference was claimed, and if so, what were the bases for claims. When counting the number of subgroup analyses, each statistical analysis evaluating treatment differences for a specific end point among different levels of one baseline factor was considered as one subgroup analysis. The articles were checked to determine whether the multiplicity issue had been addressed, especially in articles in which subgroup differences were claimed. The number of subgroup outcomes (primary or secondary end points) was also extracted.
Additional data extracted from each manuscript included the study sample size, intervention type, cancer type, cancer stage, publication year, journal name, funding source, impact factor, and whether the primary end point was met. The data extraction was performed by two investigators (S.Z. and F.L.) who were blinded to each other's results. Any discrepancy was identified and resolved successfully by the consensus from all authors of this study.
Statistical Analysis
The primary objective of our study was to describe the subgroup analyses in oncology RCT publications. The descriptive statistics included percentages and means.
RESULTS
Characteristics of the Selected RCTs
From the trials initially screened, 221 RCTs were included in this study on the basis of the full articles. The selection process and reasons for exclusion are shown in Figure 1 .
The characteristics of the publications included in this study are listed in Table 2 . These 221 publications reported data on 184,500 patients (mean, 835; range, 184 to 7,576). The most common tumor types explored were breast cancer (23.5%) and lung cancer (20.4%). Chemotherapy plus targeted therapy was the most common intervention (32.6%). Most trials (66.5%) were at least partially funded by industry. Forty percent of the trials were positive on the basis of the Table 2 ). Eighty-one percent of the articles reported treatments for metastatic cancer.
Subgroup Analyses
Among 221 eligible articles, a total of 188 publications reported subgroup analyses (85%). Out of the 188 trials that reported subgroup analyses, these analyses were mentioned in the Methods section for 91 trials (49%), in the Results section for 184 trials (98%), and in the Discussion section for 123 trials (66%); subgroup analyses were reported in an online appendix for 27 trials (14%). Forest plots were used to show the results of subgroup analyses in 69% of the trials.
Other characteristics of the reports are shown in Table 3 . In general, we were unable to determine the number of subgroup analyses conducted. For example, it was reported that ". . . only subgroup analyses with at least 10 patients per group are presented." Only a few In 32% of the trials, it was unclear whether the subgroup analyses were prespecified or post hoc, and subgroup analyses of 26% trials were post hoc. Full prespecification of all subgroups was done in only 31% trials. Interaction tests were reported to have been used to assess the heterogeneity of treatment effects for all or some subgroup analyses in only 34% of trials. However, the majority of the trials evaluated end points separately within subgroups (80% reported a subgroup P value and/or CI). More than 7% of the trials reported subgroup analyses without any statistical analyses (Table 3) .
Investigators in 102 trials claimed heterogeneity of treatment effects between at least one subject subgroup and the overall study population (54%; Table 4 ). For 18 (18%) of these trials, the claims were based on nominally significant interaction test results, whereas the claims were based only on within-subgroup comparisons for the majority of the trials (77%). For the remaining five trials with claims, the basis of claims was just visual inspection without any statistical analyses. Thirty percent of the claims were presented in the abstracts of the articles. When heterogeneity in the treatment effect was reported, only six trials cautioned about multiplicity (5.9%). Full prespecification for subgroup claims were only done in 35% trials. At least 37% of subgroup claims were based on post hoc subgroup analyses. Of publications with claims, 62% made more than one claim, with a maximum 10 claims. The other characteristics for the claimed articles are listed in Table 4 .
DISCUSSION
Efforts to improve reporting clinical trial results have led to the development of guidelines such as those recommended by the CONSORT group. 3, 4 Transparent and comprehensive reporting of subgroup analyses in oncology clinical trial publications is of critical importance. Despite recommendations from the CONSORT statement published more than a decade ago, our study shows that the reporting of subgroup analyses in cancer clinical trial publications is neither uniform nor complete. This heterogeneity complicates the interpretation of subgroup analyses by physicians and highlights the need to establish uniform standards for the reporting and analysis of subgroup analyses in oncology studies.
Our analysis of recent studies shows that some problems are obvious in cancer RCT articles. For the majority of the studies evaluated, the number of subgroup analyses performed cannot be determined. The results of subgroup analyses were not reported for a substantial group of studies. Selective reporting in clinical trials occurs when outcome data are collected but not reported, and when investigators do many analyses but report only the most favorable. It can distort the results of trials and bias meta-analyses. 6, 13 It was reported that some investigators selectively report only the more interesting subgroup analyses, thereby leaving the readers unaware of how many other subgroup analyses were performed and not mentioned. This problem seems ubiquitous in reporting of subgroup analyses in publications of cancer RCTs.
Subgroup analyses can pose serious concerns about multiplicity. By testing enough subgroups, a false-positive result will probably emerge by chance alone. For example, if the null hypothesis is true for each of 10 independent tests for interaction at the .05 significance level, the chance of at least one false-positive result exceeds 40%.
14, 15 Investigators might undertake many analyses but only report the significant effects. Thus, one must be cautious in the interpretation of such results. In our analysis, more than 78% of trials reported at least six subgroup analyses, whereas a maximum of 37 subgroup analyses were reported in some trials. The solution for this problem is to limit the subgroup analyses to a few potentially important questions. If the number of subgroup analyses cannot be limited, the effect of multiplicity should be carefully considered when a subgroup difference is claimed. 14 For the 102 studies with claims of subgroup analyses in our analysis, the authors discussed concerns about multiplicity in only six articles.
A prespecified subgroup analysis is one that is planned and documented before any examination of the data, preferably in the study protocol. Post hoc analyses refer to those in which the hypotheses being tested are not specified before any examination of the data. Post hoc subgroup analyses are of particular concern because it is often unclear how many were undertaken and whether some were motivated by inspection of the data. 15, 16 However, the findings from our study show that full prespecification of subgroup analyses was only performed in a minority of the trials. A substantial group of claims of subgroup differences were based on post hoc analyses, thus limiting the credibility.
Forest plots have become a useful graphical method for displaying treatment effects across subgroups, given that readers can visually capture the difference between multiple subgroups with the relevant information. Thus, the use of forest plots has been encouraged in the display of subgroup analyses in clinical trial reports. 17 However, only approximately 70% of the trials used forest plots to illustrate the results of subgroup analyses. More trials should be encouraged to use this method. Recently, evaluation of treatment heterogeneity by biomarker groups as subgroup factors has been increasing. In our analysis, biomarker-based subgroup analyses comprise 53% of the studies that reported subgroup results. If the biomarker is measured on a continuous scale, some other analytic approaches have been developed to make full use of all available information for subgroup analyses. For example, the subpopulation treatment effect pattern plot and multivariable fractional polynomial interaction plot have been used to evaluate treatment-effect heterogeneity when a biomarker is measured on a continuous scale. 18 An interaction test assesses differences in treatment effects between subgroups and involves one statistical test irrespective of the number of subgroups. In contrast, the separate subgroup methods assess treatment effects in each group independently, and they involve more than one test. This is inappropriate from a statistical point of view. 15, 19 Reliance on subgroup P values is misleading. If the overall result is significant, almost inevitably some subgroups will and some will not show significant differences, depending on chance and the small size of subgroups. Conversely, if an overall difference is not significant, some subgroups may have a larger observed treatment difference by chance, which may even reach significance. 20 Interaction test is the appropriate method to analyze subgroups. Remarkably, however, interaction tests were only used in 34% of oncology RCTs that reported subgroup analyses. The underuse of statistical tests of interaction means the element of chance gets inadequate recognition. Most clinical trials are designed to have adequate power to detect benefit in the overall study population (ie, they are not powered to detect subgroup effects). Therefore, the false-negative rate for tests of subgroup-treatment interaction effect could be high when there is a true interaction. Thus the power for interaction test is typically low. This factor might partly contribute to the underused interaction test in studies, even in those with claims of subgroup difference. In this case, meta-analyses can be used to study subgroups. Meta-analyses of individual patient data have higher power to detect significant subgroup effects compared with analyses of individual RCTs.
We found several problems in the use and reporting of subgroup analyses in recent oncology RCTs. Many subgroups were reported, although frequently they were not prespecified. The test of interaction was underused. These problems may mislead treatment decisions when particular subgroups of patients are being evaluated. Although prior analyses have addressed these issues in clinical research publications, most have focused on nononcologic diseases. 6 Hernandez et al 21 reviewed the results of 63 cardiovascular trials published and noted the similar problems of subgroup analyses. Previous studies evaluating subgroup analyses were mainly small sample size or were limited to certain journals or to a noncancer subspecialty of medicine. 8, 22 To our knowledge, our study is the first systematic review of the quality of subgroup analyses in cancer RCT publications.
There are several potential reasons for the observed incomplete and incorrect data for subgroup analyses showed in our study. The description of requirements for subgroup analyses was mainly in a few items described in the CONSORT statement. Lack of awareness of these requirements and a lack of compliance imposed by journals as a prerequisite for publications are likely contributing factors. Manuscript guidelines can limit the number of words, figures, and/or tables, which may also partially contribute to the suboptimal reporting of subgroup analyses. It is not feasible to report all subgroup analyses in the studies. However, use of carefully organized forest plots, with a link to online supplemental materials, might be a feasible way to meet a journal's manuscript requirements without affecting the quality of the analyses.
There are some potential limitations in our study. We restricted our analysis to publications reporting on phase III RCTs for solid tumor treatments in recent years, although the same CONSORT criteria should also be applied to phase II trials, hematologic malignancy trials, and trials testing multimodality treatment (eg, radiation therapy). However, regarding the significance of phase III RCTs in guiding clinical treatment, the results in our study raised concerns about the quality of subgroup analyses. We only used information that was published in the RCT reports. The information provided in the reports may not necessarily be the same as that in the RCT protocol, nor does it necessarily comprise all analyses that were performed. 6 This issue will be explored in future studies.
It is possible to make some improvements in reporting of subgroup analyses. Perhaps the CONSORT statement should introduce more detailed guidance about the use and reporting of subgroup analyses; the current guideline includes only a limited discussion about subgroup analyses. It was reported that there was an internal quality control for subgroup analyses for articles published in the New England Journal of Medicine. 22 This method may improve the quality of subgroup analyses and can be employed by other journals.
When properly planned, analyzed, reported, and interpreted, the result of subgroup analyses can provide valuable information in guiding clinical decisions. It is possible that even when the standards above are followed, some subgroup claims with important clinical implications might still be unreliable. In this case, an additional test of the validity of the subgroup claim is whether it can be replicated in other trials. Finally, to address the important clinical question that can guide clinical decisions, designing an RCT specifically targeting this subgroup would be the ultimate solution.
In summary, our study shows that there is substantial heterogeneity and selectivity in the use and reporting of subgroup analyses in publications reporting cancer RCTs. Major problems include testing of a large number of subgroups, reporting on subgroups without prespecifications, and inadequate use of interaction tests. Given the potential significance of subgroup analyses for guiding clinical oncology practice, the use and reporting of subgroup analyses should be standardized.
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